Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
20
BLRX Quote, Financials, Valuation and Earnings
Last price:
$2.81
Seasonality move
:
-4.21%
Day range:
$2.75 - $2.94
52-week range:
$2.30 - $7.77
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.77x
P/B ratio:
0.63x
Volume:
7K
Avg. volume:
13.2K
1-year change:
-8.47%
Market cap:
$12.2M
Revenue:
$29.1M
EPS (TTM):
-$1.37
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BLRX
BioLineRx Ltd.
|
$492K | -$0.77 | -95.85% | -49.07% | $20.33 |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -3.23% | -72.97% | $2.50 |
|
CGEN
Compugen Ltd.
|
$14.3M | $0.14 | -46.52% | -2.83% | $5.80 |
|
EVGN
Evogene Ltd.
|
$275K | -$0.26 | -82.93% | -68.8% | $2.50 |
|
PLUR
Pluri, Inc.
|
$638K | -$0.65 | 316.67% | -79.86% | $12.00 |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BLRX
BioLineRx Ltd.
|
$2.81 | $20.33 | $12.2M | -- | $0.00 | 0% | 0.77x |
|
CANF
Can-Fite BioPharma Ltd.
|
$6.02 | $2.50 | $7.9M | -- | $0.00 | 0% | 33.58x |
|
CGEN
Compugen Ltd.
|
$2.14 | $5.80 | $200.2M | 5.79x | $0.00 | 0% | 2.75x |
|
EVGN
Evogene Ltd.
|
$0.85 | $2.50 | $7.4M | -- | $0.00 | 0% | 1.19x |
|
PLUR
Pluri, Inc.
|
$3.53 | $12.00 | $35.5M | -- | $0.00 | 0% | 21.56x |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
$0.78 | -- | $6.8M | -- | $0.00 | 0% | 13.79x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BLRX
BioLineRx Ltd.
|
36.81% | 2.584 | 69.17% | 1.84x |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | 1.072 | -- | -- |
|
CGEN
Compugen Ltd.
|
2.8% | 2.063 | 2.07% | 6.45x |
|
EVGN
Evogene Ltd.
|
68.82% | 1.837 | 9.67% | 4.01x |
|
PLUR
Pluri, Inc.
|
172.93% | 0.067 | 98.32% | 0.40x |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
2.86% | 0.006 | 1.28% | 0.75x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BLRX
BioLineRx Ltd.
|
$225K | -$2.2M | -9.37% | -18.74% | -516.85% | -$2.1M |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CGEN
Compugen Ltd.
|
$63.8M | $56M | 54.64% | 57.22% | 83.23% | -- |
|
EVGN
Evogene Ltd.
|
-$126K | -$2.7M | -57.78% | -66.95% | -870.19% | -$3.8M |
|
PLUR
Pluri, Inc.
|
-$43K | -$6.5M | -93.31% | -5662.45% | -3285.86% | -$5.7M |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
-- | -$764K | -33.97% | -34.34% | -283.95% | -- |
BioLineRx Ltd. vs. Competitors
-
Which has Higher Returns BLRX or CANF?
Can-Fite BioPharma Ltd. has a net margin of -228.81% compared to BioLineRx Ltd.'s net margin of --. BioLineRx Ltd.'s return on equity of -18.74% beat Can-Fite BioPharma Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BLRXBioLineRx Ltd.52.45% -$0.22 $30.9M CANFCan-Fite BioPharma Ltd.-- -- -- -
What do Analysts Say About BLRX or CANF?
BioLineRx Ltd. has a consensus price target of $20.33, signalling upside risk potential of 623.61%. On the other hand Can-Fite BioPharma Ltd. has an analysts' consensus of $2.50 which suggests that it could grow by 730.57%. Given that Can-Fite BioPharma Ltd. has higher upside potential than BioLineRx Ltd., analysts believe Can-Fite BioPharma Ltd. is more attractive than BioLineRx Ltd..
Company Buy Ratings Hold Ratings Sell Ratings BLRXBioLineRx Ltd.2 0 0 CANFCan-Fite BioPharma Ltd.1 1 0 -
Is BLRX or CANF More Risky?
BioLineRx Ltd. has a beta of 1.309, which suggesting that the stock is 30.875% more volatile than S&P 500. In comparison Can-Fite BioPharma Ltd. has a beta of 1.011, suggesting its more volatile than the S&P 500 by 1.09%.
-
Which is a Better Dividend Stock BLRX or CANF?
BioLineRx Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can-Fite BioPharma Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLineRx Ltd. pays -- of its earnings as a dividend. Can-Fite BioPharma Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLRX or CANF?
BioLineRx Ltd. quarterly revenues are $429K, which are larger than Can-Fite BioPharma Ltd. quarterly revenues of --. BioLineRx Ltd.'s net income of -$981.6K is higher than Can-Fite BioPharma Ltd.'s net income of --. Notably, BioLineRx Ltd.'s price-to-earnings ratio is -- while Can-Fite BioPharma Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLineRx Ltd. is 0.77x versus 33.58x for Can-Fite BioPharma Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLRXBioLineRx Ltd.0.77x -- $429K -$981.6K CANFCan-Fite BioPharma Ltd.33.58x -- -- --
-
Which has Higher Returns BLRX or CGEN?
Compugen Ltd. has a net margin of -228.81% compared to BioLineRx Ltd.'s net margin of 84.43%. BioLineRx Ltd.'s return on equity of -18.74% beat Compugen Ltd.'s return on equity of 57.22%.
Company Gross Margin Earnings Per Share Invested Capital BLRXBioLineRx Ltd.52.45% -$0.22 $30.9M CGENCompugen Ltd.94.75% $0.60 $105.7M -
What do Analysts Say About BLRX or CGEN?
BioLineRx Ltd. has a consensus price target of $20.33, signalling upside risk potential of 623.61%. On the other hand Compugen Ltd. has an analysts' consensus of $5.80 which suggests that it could grow by 171.03%. Given that BioLineRx Ltd. has higher upside potential than Compugen Ltd., analysts believe BioLineRx Ltd. is more attractive than Compugen Ltd..
Company Buy Ratings Hold Ratings Sell Ratings BLRXBioLineRx Ltd.2 0 0 CGENCompugen Ltd.5 0 0 -
Is BLRX or CGEN More Risky?
BioLineRx Ltd. has a beta of 1.309, which suggesting that the stock is 30.875% more volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.896, suggesting its more volatile than the S&P 500 by 189.647%.
-
Which is a Better Dividend Stock BLRX or CGEN?
BioLineRx Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLineRx Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLRX or CGEN?
BioLineRx Ltd. quarterly revenues are $429K, which are smaller than Compugen Ltd. quarterly revenues of $67.3M. BioLineRx Ltd.'s net income of -$981.6K is lower than Compugen Ltd.'s net income of $56.8M. Notably, BioLineRx Ltd.'s price-to-earnings ratio is -- while Compugen Ltd.'s PE ratio is 5.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLineRx Ltd. is 0.77x versus 2.75x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLRXBioLineRx Ltd.0.77x -- $429K -$981.6K CGENCompugen Ltd.2.75x 5.79x $67.3M $56.8M
-
Which has Higher Returns BLRX or EVGN?
Evogene Ltd. has a net margin of -228.81% compared to BioLineRx Ltd.'s net margin of -874.68%. BioLineRx Ltd.'s return on equity of -18.74% beat Evogene Ltd.'s return on equity of -66.95%.
Company Gross Margin Earnings Per Share Invested Capital BLRXBioLineRx Ltd.52.45% -$0.22 $30.9M EVGNEvogene Ltd.-40.39% $0.44 $19.8M -
What do Analysts Say About BLRX or EVGN?
BioLineRx Ltd. has a consensus price target of $20.33, signalling upside risk potential of 623.61%. On the other hand Evogene Ltd. has an analysts' consensus of $2.50 which suggests that it could grow by 195.02%. Given that BioLineRx Ltd. has higher upside potential than Evogene Ltd., analysts believe BioLineRx Ltd. is more attractive than Evogene Ltd..
Company Buy Ratings Hold Ratings Sell Ratings BLRXBioLineRx Ltd.2 0 0 EVGNEvogene Ltd.1 0 0 -
Is BLRX or EVGN More Risky?
BioLineRx Ltd. has a beta of 1.309, which suggesting that the stock is 30.875% more volatile than S&P 500. In comparison Evogene Ltd. has a beta of 1.362, suggesting its more volatile than the S&P 500 by 36.219%.
-
Which is a Better Dividend Stock BLRX or EVGN?
BioLineRx Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evogene Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLineRx Ltd. pays -- of its earnings as a dividend. Evogene Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLRX or EVGN?
BioLineRx Ltd. quarterly revenues are $429K, which are larger than Evogene Ltd. quarterly revenues of $312K. BioLineRx Ltd.'s net income of -$981.6K is higher than Evogene Ltd.'s net income of -$2.7M. Notably, BioLineRx Ltd.'s price-to-earnings ratio is -- while Evogene Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLineRx Ltd. is 0.77x versus 1.19x for Evogene Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLRXBioLineRx Ltd.0.77x -- $429K -$981.6K EVGNEvogene Ltd.1.19x -- $312K -$2.7M
-
Which has Higher Returns BLRX or PLUR?
Pluri, Inc. has a net margin of -228.81% compared to BioLineRx Ltd.'s net margin of -3470.71%. BioLineRx Ltd.'s return on equity of -18.74% beat Pluri, Inc.'s return on equity of -5662.45%.
Company Gross Margin Earnings Per Share Invested Capital BLRXBioLineRx Ltd.52.45% -$0.22 $30.9M PLURPluri, Inc.-21.72% -$0.71 $25.4M -
What do Analysts Say About BLRX or PLUR?
BioLineRx Ltd. has a consensus price target of $20.33, signalling upside risk potential of 623.61%. On the other hand Pluri, Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 239.93%. Given that BioLineRx Ltd. has higher upside potential than Pluri, Inc., analysts believe BioLineRx Ltd. is more attractive than Pluri, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BLRXBioLineRx Ltd.2 0 0 PLURPluri, Inc.1 0 0 -
Is BLRX or PLUR More Risky?
BioLineRx Ltd. has a beta of 1.309, which suggesting that the stock is 30.875% more volatile than S&P 500. In comparison Pluri, Inc. has a beta of 0.663, suggesting its less volatile than the S&P 500 by 33.7%.
-
Which is a Better Dividend Stock BLRX or PLUR?
BioLineRx Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pluri, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLineRx Ltd. pays -- of its earnings as a dividend. Pluri, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLRX or PLUR?
BioLineRx Ltd. quarterly revenues are $429K, which are larger than Pluri, Inc. quarterly revenues of $198K. BioLineRx Ltd.'s net income of -$981.6K is higher than Pluri, Inc.'s net income of -$6.9M. Notably, BioLineRx Ltd.'s price-to-earnings ratio is -- while Pluri, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLineRx Ltd. is 0.77x versus 21.56x for Pluri, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLRXBioLineRx Ltd.0.77x -- $429K -$981.6K PLURPluri, Inc.21.56x -- $198K -$6.9M
-
Which has Higher Returns BLRX or XTLB?
XTL Biopharmaceuticals Ltd. has a net margin of -228.81% compared to BioLineRx Ltd.'s net margin of -341.36%. BioLineRx Ltd.'s return on equity of -18.74% beat XTL Biopharmaceuticals Ltd.'s return on equity of -34.34%.
Company Gross Margin Earnings Per Share Invested Capital BLRXBioLineRx Ltd.52.45% -$0.22 $30.9M XTLBXTL Biopharmaceuticals Ltd.-- -$0.16 $5.9M -
What do Analysts Say About BLRX or XTLB?
BioLineRx Ltd. has a consensus price target of $20.33, signalling upside risk potential of 623.61%. On the other hand XTL Biopharmaceuticals Ltd. has an analysts' consensus of -- which suggests that it could grow by 3770.97%. Given that XTL Biopharmaceuticals Ltd. has higher upside potential than BioLineRx Ltd., analysts believe XTL Biopharmaceuticals Ltd. is more attractive than BioLineRx Ltd..
Company Buy Ratings Hold Ratings Sell Ratings BLRXBioLineRx Ltd.2 0 0 XTLBXTL Biopharmaceuticals Ltd.0 0 0 -
Is BLRX or XTLB More Risky?
BioLineRx Ltd. has a beta of 1.309, which suggesting that the stock is 30.875% more volatile than S&P 500. In comparison XTL Biopharmaceuticals Ltd. has a beta of 1.193, suggesting its more volatile than the S&P 500 by 19.26%.
-
Which is a Better Dividend Stock BLRX or XTLB?
BioLineRx Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XTL Biopharmaceuticals Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLineRx Ltd. pays -- of its earnings as a dividend. XTL Biopharmaceuticals Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLRX or XTLB?
BioLineRx Ltd. quarterly revenues are $429K, which are larger than XTL Biopharmaceuticals Ltd. quarterly revenues of $162K. BioLineRx Ltd.'s net income of -$981.6K is lower than XTL Biopharmaceuticals Ltd.'s net income of -$553K. Notably, BioLineRx Ltd.'s price-to-earnings ratio is -- while XTL Biopharmaceuticals Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLineRx Ltd. is 0.77x versus 13.79x for XTL Biopharmaceuticals Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLRXBioLineRx Ltd.0.77x -- $429K -$981.6K XTLBXTL Biopharmaceuticals Ltd.13.79x -- $162K -$553K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
34
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
46
ZD alert for Mar 4
Ziff Davis, Inc. [ZD] is up 3.64% over the past day.
Buy
54
KORU alert for Mar 5
Direxion Daily MSCI South Korea Bull 3X Shares [KORU] is up 5.43% over the past day.
Sell
40
PSIX alert for Mar 4
Power Solutions International, Inc. [PSIX] is down 1.4% over the past day.
